Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 345 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $86.10, for a total value of $29,704.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Penumbra, Inc. (NYSE PEN) traded up 1.08% during trading on Friday, hitting $84.45. The stock had a trading volume of 117,627 shares. The firm’s 50 day moving average is $86.08 and its 200 day moving average is $81.60. The firm has a market cap of $2.84 billion, a price-to-earnings ratio of 302.69 and a beta of 0.15. Penumbra, Inc. has a 1-year low of $56.05 and a 1-year high of $91.00.
Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.04. Penumbra had a negative net margin of 2.31% and a negative return on equity of 2.25%. The business had revenue of $73.21 million for the quarter, compared to analysts’ expectations of $71.08 million. During the same quarter in the prior year, the firm posted $0.07 EPS. The business’s quarterly revenue was up 26.4% compared to the same quarter last year. On average, analysts anticipate that Penumbra, Inc. will post ($0.13) earnings per share for the current year.
WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/07/30/penumbra-inc-pen-director-sells-29704-50-in-stock-updated.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System increased its position in shares of Penumbra by 0.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 13,245 shares of the company’s stock worth $845,000 after buying an additional 120 shares during the period. State Street Corp increased its position in shares of Penumbra by 9.4% in the fourth quarter. State Street Corp now owns 472,199 shares of the company’s stock worth $30,130,000 after buying an additional 40,596 shares during the period. Pioneer Investment Management Inc. increased its position in shares of Penumbra by 27.9% in the first quarter. Pioneer Investment Management Inc. now owns 86,502 shares of the company’s stock worth $7,219,000 after buying an additional 18,873 shares during the period. Eagle Asset Management Inc. purchased a new position in shares of Penumbra during the first quarter worth approximately $15,865,000. Finally, Next Century Growth Investors LLC increased its position in shares of Penumbra by 1.8% in the first quarter. Next Century Growth Investors LLC now owns 141,981 shares of the company’s stock worth $11,848,000 after buying an additional 2,545 shares during the period. Hedge funds and other institutional investors own 68.67% of the company’s stock.
A number of analysts have issued reports on PEN shares. BidaskClub raised Penumbra from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. BMO Capital Markets reissued a “buy” rating and issued a $96.00 price target on shares of Penumbra in a research note on Friday, June 16th. Canaccord Genuity reissued a “buy” rating and issued a $94.00 price target on shares of Penumbra in a research note on Tuesday, June 13th. Finally, Zacks Investment Research lowered Penumbra from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th.
About Penumbra
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
